Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
siliconbiosystems.com

See what CB Insights has to offer

Founded Year

1999

Stage

Acquired | Acquired

About Silicon Biosystems

Silicon Biosystems has developed a set of solutions in the field of lab-on-a-chip technologies targeted at miniaturized single-cell-biology testing, fully exploiting the high potential of microelectronics. The diagnostic approach has led to the possibility of controlling individual cells and micro-particles inside a micro-chamber. Silicon Biosystems technology aims to manage cells on a microelectronic chip, using software control and incorporating sensors to detect the results of complex procedures. Easier recovery of rare fetal cells from maternal blood in prenatal diagnosis can become a routine and non-invasive prenatal procedure, effectively replacing amniocentesis and chorionic villus sampling currently adopted for this purpose. Further applications include the isolation of tumour stem cells, which can be studied in order to define their molecular profiles, detect pre-malignant lesions and target therapies.

Silicon Biosystems Headquarter Location

Via Giuseppe di Vittorio, 21 b/3

Castel Maggiore, 40013,

Italy

+39 051 9944100

Latest Silicon Biosystems News

New Products Posted to GenomeWeb: Thermo Fisher, Personalis, Menarini Silicon Biosystems, More

Dec 17, 2021

Save for later Thermo Fisher Scientific Ion Torrent Oncomine Myeloid Assay GX v2 Thermo Fisher Scientific has released the Ion Torrent Oncomine Myeloid Assay GX v2, a next-generation sequencing assay that allows researchers to gather comprehensive mutational results from myeloid samples in a single day using the company's Ion Torrent Genexus System. The Oncomine Myeloid Assay GX v2 offers a comprehensive panel to profile key biomarkers for all major myeloid disorders. It's optimized to detect a wide range of variants, including challenging-to-sequence targets such as FLT3-ITD, CALR, and CEBPA, Thermo Fisher said. The updates for this version of the assay include additional DNA and RNA targets, improved sequencing of key GC-rich regions, and the ability to run the RNA and DNA panels separately. The assay also features an automated workflow, enabling samples to be processed from specimen to report with only 20 minutes of hands-on time for technicians and minimal user intervention; an expanded panel with simultaneous profiling of 45 genes and 30 fusion drivers covering more than 700 unique fusions; full specimen coverage, including whole blood, peripheral blood lymphocytes, and bone marrow; and integrated reporting, with annotated variant reports and the latest relevant evidence from public data sources. Personalis NeXT Personal Personalis has launched NeXT Personal, a tumor-informed liquid biopsy assay designed to detect and quantify molecular residual disease and recurrence in patients previously diagnosed with cancer. The assay boasts sensitivity down to the 1 part-per-million range and uses whole-genome sequencing of a patient's tumor to identify up to 1,800 somatic variants that are subsequently used to create a personalized liquid biopsy panel for each patient. With broader content than other available assays, these panels can also be used to detect clinically relevant alterations with a potential impact on therapeutic decision-making. Personalis said NeXT Personal is currently for research use only and that it plans to release it as a clinical test next year. Menarini Silicon Biosystems DEPArray PLUS Application Menarini Silicon Biosystems has launched its FFPE Rescue Application to enable molecular testing on formalin-fixed, paraffin-embedded samples with low tumor cell contents. Enabled by the sorting capabilities of the company's DEPArray PLUS instrument, the application can be used to isolate a sufficient number of tumor cells to generate relevant molecular data, even from FFPE tissues that were previously discarded from conventional next-generation sequencing processing, the company said. As such, the workflow can reduce the failure rates of FFPE molecular analyses and provide clinical researchers with valuable information about actionable mutations, potentially improving clinical trial recruitment and allowing more patients to access new targeted therapies, the company added. For more new products and services, please visit the New Products page on our website.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Silicon Biosystems

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silicon Biosystems is included in 1 Expert Collection, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Silicon Biosystems Patents

Silicon Biosystems has filed 26 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/14/2014

1/19/2021

Clusters of differentiation, Oncology, Transcription factors, Cell biology, Biotechnology

Grant

Application Date

11/14/2014

Grant Date

1/19/2021

Title

Related Topics

Clusters of differentiation, Oncology, Transcription factors, Cell biology, Biotechnology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.